PMC10435320_01
Hepatic cavernous hemangioma and changes. (A) taken in January 2022, shows the radiological presentation of a large hepatic cavernous hemangioma on the right lobe. (B) taken in June 2022 after switching from Camrelizumab to Tislelizumab, demonstrates the changes observed, with a significant reduction and near disappearance of the hepatic cavernous hemangioma.
fonc-13-1221309-g001.jpg
PMC10435320_01_fonc-13-1221309-g001.jpg
f1
The treatment response assessment after the 2nd and 4th cycles indicated Partial Remission (PR), while the assessment after the 6th and 8th cycles showed Stable Disease (SD).In January 2022, a follow-up examination revealed a nodular lesion in the right liver ( Figure 1A ). Regular follow-up examinations every two months indicated sustained stable disease in the primary lesion, and the hepatic cavernous hemangioma disappeared ( Figure 1B ).
PMC10435320_02
Hepatic cavernous hemangioma and changes. (A) taken in October 2022, shows the initial imaging findings of two hepatic cavernous hemangiomas in the left liver. (B) taken in February 2023, demonstrates the changes following discontinuation of Camrelizumab, with the hepatic cavernous hemangioma almost disappearing.
fonc-13-1221309-g002.jpg
PMC10435320_02_fonc-13-1221309-g002.jpg
f2
In October 2022, a liver nodule was discovered in the left liver lobe on abdominal CT ( Figure 2A ). Subsequently, the hepatic cavernous hemangioma disappeared ( Figure 2B ), and no further drug-related adverse reactions occurred.